You are here
Global Kinetics Corporation’s PKG® Smartwatch Provides Clinically Meaningful Improvement in Parkinson’s Disease Symptom Assessment, Management and Medication Optimization, As Well As Per Projected Patient Cost Savings
Data Recently Presented at the 2018 International Congress of Parkinson’s Disease and Movement Disorders
PORTSMOUTH, N.H., LONDON and MELBOURNE, Australia, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Global Kinetics Pty Ltd. (GKC) today announced data recently presented at a poster presentation session during the International Congress of Parkinson’s Disease (PD) and Movement Disorders (MDS), held October 5-9, in Hong Kong, China. The data highlighted how the Company’s Personal KinetiGraph® (PKG®) technology provided clinically meaningful improvements in PD symptom assessment, management and medication optimization, as well as a projected average cost saving range of $962 - $1,719.42 per patient.
The PKG device, FDA-cleared and CE-marked, is a first-of-its-kind wearable technology that provides clinicians with a passive, continuous, objective, ambulatory assessment of the treatable and disabling symptoms of PD, including bradykinesia, dyskinesia, and tremor.
John Schellhorn, CEO of Global Kinetics Corporation, said, “In order for the Parkinson’s disease community to continue to work toward optimizing clinical care for this degenerative disease, we need to combine our efforts and collaborate on as many research initiatives as possible. We are pleased to share this data, as well as having our PKG device be used as an objective measurement tool in the clinical care setting. We are also excited that our PKG smartwatch is being used in multiple clinical studies conducted by pharmaceutical and biotechnology companies to evaluate potential new therapies.”
In one study with 27,834 deidentified PKG users worldwide from 2012 – 2018, researchers found that a meaningful proportion of patients had suboptimal PD motor symptoms management, with 54% having uncontrolled but likely treatable bradykinesia and 10% showing uncontrolled, likely treatable dyskinesia.i Upon subsequent PKG use, there was a significant improvement in motor symptoms, demonstrating that the objective measurement data provided by the technology can be used to enhance clinical decision making to improve motor symptom management.i A separate open-label study with 28 patients at a movement disorder practice found similar results, noting that the PKG contributed to clinically meaningful improvements in symptoms assessment, overall symptoms and optimized medication use.ii
In addition, a health economic analysis of PKG utilization to enhance clinical care quantified the economic cost savings and incremental outcomes for patients who have their medication changed following assessment with the wearable device, with the improved PD management providing a projected cost savings of $1,719.42 per patient over a 12-month period.iii Supporting this finding, a smaller study found that PKG use improved disease management and contributed to a projected total cost savings of $962 per patient from lower resource utilization.iv
About Global Kinetics Pty Ltd.
Global Kinetics Pty Ltd. is committed to improving the lives of those with Parkinson’s disease with advanced medical technologies. The company was formed in 2007 to commercialise its lead product, the Personal KinetiGraph® (PKG®), also known as the Parkinson’s KinetiGraph® outside the USA. Developed in conjunction with the world-renowned Florey Institute of Neuroscience & Mental Health in Melbourne, Australia, the PKG enables the precise monitoring, quantification, and reporting of movement symptoms in Parkinson’s. To date, Global Kinetics has supported clinical decisions for doctors who treat patients with Parkinson’s disease across 17 countries with more than 3,000,000 hours of clinical data from our FDA-cleared, CE-marked PKG wearable device. Global Kinetics, a privately held company, is headquartered in Melbourne, Australia with offices in London, UK, Minneapolis, MN, and Portsmouth, NH, USA.
For more information, visit: www.globalkineticscorporation.com
Follow our LinkedIn updates: https://www.linkedin.com/company/globalkineticscorp
Chantal Beaudry / Amy Feldman
+1 (646) 871-8480 / +1 (212) 867-1770
i Lynch PM, Rahwa R, Bergquist F, and Horne M (2018 October). Objective Data in Parkinson’s Disease: A Description of Over 27,000 Parkinson’s Symptom Scores Across the World Using the Personal KinetiGraph™ (PKG™). Poster presented at International Congress of Parkinson’s Disease and Movement Disorders, Hong Kong, China.
ii FB Nahab, HA Abuhussain, L Moreno (2018 October). Personal KinetiGraph™ Movement Recording System: An Assessment of Utility in a Movement Disorder Clinic. Poster presented at International Congress of Parkinson’s Disease and Movement Disorders, Hong Kong, China.
iii Lynch PM, Jackson D, Tilden D, Horne M (2018 October). Costs and outcomes for Parkinson’s disease patients who have their management adjusted by Personal KinetiGraph (PKG). Poster presented at International Congress of Parkinson’s Disease and Movement Disorders, Hong Kong, China.
iv Lynch PM, Jackson D, Tilden D, Horne M (2018 October). Pilot economic evaluation of Personal KinetiGraph (PKG) for management of Parkinson’s disease in Australia. Poster presented at International Congress of Parkinson’s Disease and Movement Disorders, Hong Kong, China.